title: Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection.
abstract: BACKGROUND
  Long lasting hepatocytes damage related to HCV infection stimulates liver fibrosis resulting in cirrhosis, hepatic failure and hepatocellular carcinoma. Until 2011 the only therapeutic option was 24-48 weeks of pegylated interferon alfa and ribavirin (RBV) with efficacy of 40-70%. New generation of direct-acting antivirals (DAA), available from 2014, can be combined and improve efficacy above 90% with 12 weeks of treatment.
  
  
  METHODS
  In this article we describe the first registered all-oral regimen consisting of three DAA - ombitasvir (OBV), paritaprevir (PTV) and dasabuvir (DSV) that became available in EU in 2015 to cure patients infected with HCV genotype 1 and 4. We performed a literature search focusing on efficacy and safety data from Phase 1-3 clinical studies and few real-world data.
  
  
  CONCLUSIONS
  OBV/PTV/r±DSV±RBV provided an opportunity to cure almost all patients including cirrhotics and non-responders to previous therapy. This treatment is currently recommended as a first line regimen. However, there is still a need for real-world data. In coming years this medication will probably be replaced with the next DAA generation with improved characteristics such as a shorter treatment duration, improved safety and resistance profile.
authors.affiliation: a Department of Infectious Diseases and Hepatology , Myedical University of Bialystok , Bialystok, Poland.
authors.forename: Mariusz
authors.initials: M
authors.lastname: Łucejko
authors.affiliation: a Department of Infectious Diseases and Hepatology , Myedical University of Bialystok , Bialystok, Poland.
authors.forename: Anna
authors.initials: A
authors.lastname: Parfieniuk-Kowerda
authors.affiliation: a Department of Infectious Diseases and Hepatology , Myedical University of Bialystok , Bialystok, Poland.
authors.forename: Robert
authors.initials: R
authors.lastname: Flisiak
mesh_terms: D015081:2-Naphthylamine; D000813:Anilides / Q000494:pharmacology / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002219:Carbamates / Q000494:pharmacology / Q000627:therapeutic use*; D003521:Cyclopropanes; D004359:Drug Therapy, Combination / Q000379:methods*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D047029:Lactams, Macrocyclic; D047028:Macrocyclic Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D011392:Proline / Q000031:analogs & derivatives; D019438:Ritonavir / Q000494:pharmacology / Q000627:therapeutic use*; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*; D014498:Uracil / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D014633:Valine
chemical_list: D000813:Anilides; D000998:Antiviral Agents; D002219:Carbamates; D003521:Cyclopropanes; D047029:Lactams, Macrocyclic; D047028:Macrocyclic Compounds; D013449:Sulfonamides; C586094:ombitasvir; D014498:Uracil; D011392:Proline; D015081:2-Naphthylamine; C588260:dasabuvir; D014633:Valine; D019438:Ritonavir; C585405:paritaprevir
keywords: HCV; Viral hepatitis; dasabuvir; direct-acting antivirals; ombitasvir; paritaprevir; ritonavir